Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group.

Sarcoma

Marec-Berard P, Segura-Ferlay C, Tabone MD, Pacquement H, Lervat C, Gentet JC, Schmitt C, Gaspar N, Brugières L.
PMID: 24672280
Sarcoma. 2014;2014:475067. doi: 10.1155/2014/475067. Epub 2014 Feb 04.

Introduction. Osteosarcoma relapse has a poor prognosis, with less than 25% survival at 5 years. We describe the experience of the French Society of Paediatric Oncology (SFCE) with high dose (HD) thiotepa and autologous stem cell transplantation (ASCT) in...

Cite
Marec-Berard P, Segura-Ferlay C, Tabone MD, et al. High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group. Sarcoma. 2014;2014:475067doi: 10.1155/2014/475067.
Marec-Berard, P., Segura-Ferlay, C., Tabone, M. D., Pacquement, H., Lervat, C., Gentet, J. C., Schmitt, C., Gaspar, N., & Brugières, L. (2014). High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group. Sarcoma, 2014475067. https://doi.org/10.1155/2014/475067
Marec-Berard, Perrine, et al. "High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group." Sarcoma vol. 2014 (2014): 475067. doi: https://doi.org/10.1155/2014/475067
Marec-Berard P, Segura-Ferlay C, Tabone MD, Pacquement H, Lervat C, Gentet JC, Schmitt C, Gaspar N, Brugières L. High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group. Sarcoma. 2014;2014:475067. doi: 10.1155/2014/475067. Epub 2014 Feb 04. PMID: 24672280; PMCID: PMC3941142.
Copy Download .nbib Format: NLM
Subcutaneous implantable pleural port catheter in the management of malignant pleural effusions in young patients with solid tumors: A new option in the armamentarium of symptomatic treatment.

Pediatric blood & cancer

Malterre A, Cohen-Gogo S, Kriegel I, d'Avout Fourdinier P, Bouleuc C, Lemelle L, Surun A, Cordero C, Pacquement H, Orbach D.
PMID: 34048136
Pediatr Blood Cancer. 2021 Aug;68(8):e29109. doi: 10.1002/pbc.29109. Epub 2021 May 28.

The contribution of subcutaneous implantable pleural port catheter (SIPP) for malignant pleural effusions (MPE) management in young patients with cancer, in a palliative care setting is not well explored. This monocentric series analyzed 38 patients, median age 18 years...

Cite
Malterre A, Cohen-Gogo S, Kriegel I, et al. Subcutaneous implantable pleural port catheter in the management of malignant pleural effusions in young patients with solid tumors: A new option in the armamentarium of symptomatic treatment. Pediatr Blood Cancer. 2021;68(8):e29109doi: 10.1002/pbc.29109.
Malterre, A., Cohen-Gogo, S., Kriegel, I., d'Avout Fourdinier, P., Bouleuc, C., Lemelle, L., Surun, A., Cordero, C., Pacquement, H., & Orbach, D. (2021). Subcutaneous implantable pleural port catheter in the management of malignant pleural effusions in young patients with solid tumors: A new option in the armamentarium of symptomatic treatment. Pediatric blood & cancer, 68(8), e29109. https://doi.org/10.1002/pbc.29109
Malterre, Aline, et al. "Subcutaneous implantable pleural port catheter in the management of malignant pleural effusions in young patients with solid tumors: A new option in the armamentarium of symptomatic treatment." Pediatric blood & cancer vol. 68,8 (2021): e29109. doi: https://doi.org/10.1002/pbc.29109
Malterre A, Cohen-Gogo S, Kriegel I, d'Avout Fourdinier P, Bouleuc C, Lemelle L, Surun A, Cordero C, Pacquement H, Orbach D. Subcutaneous implantable pleural port catheter in the management of malignant pleural effusions in young patients with solid tumors: A new option in the armamentarium of symptomatic treatment. Pediatr Blood Cancer. 2021 Aug;68(8):e29109. doi: 10.1002/pbc.29109. Epub 2021 May 28. PMID: 34048136.
Copy Download .nbib Format: NLM
Subcutaneous implantable pleural port catheter in the management of malignant pleural effusions in young patients with solid tumors: A new option in the armamentarium of symptomatic treatment.

Pediatric blood & cancer

Malterre A, Cohen-Gogo S, Kriegel I, d'Avout Fourdinier P, Bouleuc C, Lemelle L, Surun A, Cordero C, Pacquement H, Orbach D.
PMID: 34048136
Pediatr Blood Cancer. 2021 Aug;68(8):e29109. doi: 10.1002/pbc.29109. Epub 2021 May 28.

The contribution of subcutaneous implantable pleural port catheter (SIPP) for malignant pleural effusions (MPE) management in young patients with cancer, in a palliative care setting is not well explored. This monocentric series analyzed 38 patients, median age 18 years...

Cite
Malterre A, Cohen-Gogo S, Kriegel I, et al. Subcutaneous implantable pleural port catheter in the management of malignant pleural effusions in young patients with solid tumors: A new option in the armamentarium of symptomatic treatment. Pediatr Blood Cancer. 2021;68(8):e29109doi: 10.1002/pbc.29109.
Malterre, A., Cohen-Gogo, S., Kriegel, I., d'Avout Fourdinier, P., Bouleuc, C., Lemelle, L., Surun, A., Cordero, C., Pacquement, H., & Orbach, D. (2021). Subcutaneous implantable pleural port catheter in the management of malignant pleural effusions in young patients with solid tumors: A new option in the armamentarium of symptomatic treatment. Pediatric blood & cancer, 68(8), e29109. https://doi.org/10.1002/pbc.29109
Malterre, Aline, et al. "Subcutaneous implantable pleural port catheter in the management of malignant pleural effusions in young patients with solid tumors: A new option in the armamentarium of symptomatic treatment." Pediatric blood & cancer vol. 68,8 (2021): e29109. doi: https://doi.org/10.1002/pbc.29109
Malterre A, Cohen-Gogo S, Kriegel I, d'Avout Fourdinier P, Bouleuc C, Lemelle L, Surun A, Cordero C, Pacquement H, Orbach D. Subcutaneous implantable pleural port catheter in the management of malignant pleural effusions in young patients with solid tumors: A new option in the armamentarium of symptomatic treatment. Pediatr Blood Cancer. 2021 Aug;68(8):e29109. doi: 10.1002/pbc.29109. Epub 2021 May 28. PMID: 34048136.
Copy Download .nbib Format: NLM
Parental comprehension of the benefits/risks of first-line randomised clinical trials in children with solid tumours: a two-stage cross-sectional interview study.

BMJ open

Chappuy H, Bouazza N, Minard-Colin V, Patte C, Brugières L, Landman-Parker J, Auvrignon A, Davous D, Pacquement H, Orbach D, Tréluyer JM, Doz F.
PMID: 23793670
BMJ Open. 2013 May 28;3(5). doi: 10.1136/bmjopen-2013-002733.

OBJECTIVES: To analyse the parental understanding of informed consent information in first-line randomised clinical trials (RCTs) including children with malignant solid tumours and to assess parents' needs for decision-making.DESIGN: Observational prospective study.SETTING: 3 paediatric oncology centres in the Parisian...

Cite
Chappuy H, Bouazza N, Minard-Colin V, et al. Parental comprehension of the benefits/risks of first-line randomised clinical trials in children with solid tumours: a two-stage cross-sectional interview study. BMJ Open. 2013;3(5)doi: 10.1136/bmjopen-2013-002733.
Chappuy, H., Bouazza, N., Minard-Colin, V., Patte, C., Brugières, L., Landman-Parker, J., Auvrignon, A., Davous, D., Pacquement, H., Orbach, D., Tréluyer, J. M., & Doz, F. (2013). Parental comprehension of the benefits/risks of first-line randomised clinical trials in children with solid tumours: a two-stage cross-sectional interview study. BMJ open, 3(5), . https://doi.org/10.1136/bmjopen-2013-002733
Chappuy, Hélène, et al. "Parental comprehension of the benefits/risks of first-line randomised clinical trials in children with solid tumours: a two-stage cross-sectional interview study." BMJ open vol. 3,5 (2013). doi: https://doi.org/10.1136/bmjopen-2013-002733
Chappuy H, Bouazza N, Minard-Colin V, Patte C, Brugières L, Landman-Parker J, Auvrignon A, Davous D, Pacquement H, Orbach D, Tréluyer JM, Doz F. Parental comprehension of the benefits/risks of first-line randomised clinical trials in children with solid tumours: a two-stage cross-sectional interview study. BMJ Open. 2013 May 28;3(5). doi: 10.1136/bmjopen-2013-002733. PMID: 23793670; PMCID: PMC3657641.
Copy Download .nbib Format: NLM
Successive Osteosarcoma Relapses after the First Line O2006/Sarcome-09 Trial: What Can We Learn for Further Phase-II Trials?.

Cancers

Thebault E, Piperno-Neumann S, Tran D, Pacquement H, Marec-Berard P, Lervat C, Castex MP, Cleirec M, Bompas E, Vannier JP, Plantaz D, Saumet L, Verite C, Collard O, Pluchart C, Briandet C, Monard L, Brugieres L, Le Deley MC, Gaspar N.
PMID: 33918346
Cancers (Basel). 2021 Apr 02;13(7). doi: 10.3390/cancers13071683.

The purpose was to describe first and subsequent relapses in patients from the OS2006/Sarcome-09 trial, to help future trial design. We prospectively collected and analysed relapse data of all French patients included in the OS2006/Sarcome-09 trial, who had achieved...

Cite
Thebault E, Piperno-Neumann S, Tran D, et al. Successive Osteosarcoma Relapses after the First Line O2006/Sarcome-09 Trial: What Can We Learn for Further Phase-II Trials?. Cancers (Basel). 2021;13(7)doi: 10.3390/cancers13071683.
Thebault, E., Piperno-Neumann, S., Tran, D., Pacquement, H., Marec-Berard, P., Lervat, C., Castex, M. P., Cleirec, M., Bompas, E., Vannier, J. P., Plantaz, D., Saumet, L., Verite, C., Collard, O., Pluchart, C., Briandet, C., Monard, L., Brugieres, L., Le Deley, M. C., & Gaspar, N. (2021). Successive Osteosarcoma Relapses after the First Line O2006/Sarcome-09 Trial: What Can We Learn for Further Phase-II Trials?. Cancers, 13(7), . https://doi.org/10.3390/cancers13071683
Thebault, Eric, et al. "Successive Osteosarcoma Relapses after the First Line O2006/Sarcome-09 Trial: What Can We Learn for Further Phase-II Trials?." Cancers vol. 13,7 (2021). doi: https://doi.org/10.3390/cancers13071683
Thebault E, Piperno-Neumann S, Tran D, Pacquement H, Marec-Berard P, Lervat C, Castex MP, Cleirec M, Bompas E, Vannier JP, Plantaz D, Saumet L, Verite C, Collard O, Pluchart C, Briandet C, Monard L, Brugieres L, Le Deley MC, Gaspar N. Successive Osteosarcoma Relapses after the First Line O2006/Sarcome-09 Trial: What Can We Learn for Further Phase-II Trials?. Cancers (Basel). 2021 Apr 02;13(7). doi: 10.3390/cancers13071683. PMID: 33918346; PMCID: PMC8038261.
Copy Download .nbib Format: NLM
Decision-tree derivation and external validation of a new clinical decision rule (DISCERN-FN) to predict the risk of severe infection during febrile neutropenia in children treated for cancer.

The Lancet. Child & adolescent health

Delebarre M, Gonzales F, Behal H, Tiphaine A, Sudour-Bonnange H, Lutun A, Abbou S, Pertuisel S, Thouvenin-Doulet S, Pellier I, Mansuy L, Piguet C, Paillard C, Blanc L, Thebaud E, Plantaz D, Blouin P, Schneider P, Guillaumat C, Simon P, Domenech C, Pacquement H, Le Meignen M, Pluchart C, Vérite C, Plat G, Martinot A, Duhamel A, Dubos F.
PMID: 34871572
Lancet Child Adolesc Health. 2021 Dec 03; doi: 10.1016/S2352-4642(21)00337-0. Epub 2021 Dec 03.

BACKGROUND: In 2017, international guidelines proposed new management of febrile neutropenia in children with cancer, adapted to the risk of severe infection by clinical decision rules (CDRs). Until now, none of the proposed CDRs has performed well enough in...

Cite
Delebarre M, Gonzales F, Behal H, et al. Decision-tree derivation and external validation of a new clinical decision rule (DISCERN-FN) to predict the risk of severe infection during febrile neutropenia in children treated for cancer. Lancet Child Adolesc Health. 2021;doi: 10.1016/S2352-4642(21)00337-0.
Delebarre, M., Gonzales, F., Behal, H., Tiphaine, A., Sudour-Bonnange, H., Lutun, A., Abbou, S., Pertuisel, S., Thouvenin-Doulet, S., Pellier, I., Mansuy, L., Piguet, C., Paillard, C., Blanc, L., Thebaud, E., Plantaz, D., Blouin, P., Schneider, P., Guillaumat, C., Simon, P., Domenech, C., Pacquement, H., Le Meignen, M., Pluchart, C., Vérite, C., Plat, G., Martinot, A., Duhamel, A., & Dubos, F. (2021). Decision-tree derivation and external validation of a new clinical decision rule (DISCERN-FN) to predict the risk of severe infection during febrile neutropenia in children treated for cancer. The Lancet. Child & adolescent health, . https://doi.org/10.1016/S2352-4642(21)00337-0
Delebarre, Mathilde, et al. "Decision-tree derivation and external validation of a new clinical decision rule (DISCERN-FN) to predict the risk of severe infection during febrile neutropenia in children treated for cancer." The Lancet. Child & adolescent health vol. (2021). doi: https://doi.org/10.1016/S2352-4642(21)00337-0
Delebarre M, Gonzales F, Behal H, Tiphaine A, Sudour-Bonnange H, Lutun A, Abbou S, Pertuisel S, Thouvenin-Doulet S, Pellier I, Mansuy L, Piguet C, Paillard C, Blanc L, Thebaud E, Plantaz D, Blouin P, Schneider P, Guillaumat C, Simon P, Domenech C, Pacquement H, Le Meignen M, Pluchart C, Vérite C, Plat G, Martinot A, Duhamel A, Dubos F. Decision-tree derivation and external validation of a new clinical decision rule (DISCERN-FN) to predict the risk of severe infection during febrile neutropenia in children treated for cancer. Lancet Child Adolesc Health. 2021 Dec 03; doi: 10.1016/S2352-4642(21)00337-0. Epub 2021 Dec 03. PMID: 34871572.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries